<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="openVirus\examples\priya950\4-part\PMC7211204\results\search\disease\results.xml">
  <result pre="have made significant progress and are demonstrating promising efficacy in" exact="infectious disease" post="and cancer studies in small and large animal models."/>
  <result pre="progress and are demonstrating promising efficacy in infectious disease and" exact="cancer" post="studies in small and large animal models. These platforms"/>
  <result pre="and the possibility for self-administration in several indications, such as" exact="rheumatoid arthritis," post="primary immunodeficiencies, and multiple sclerosis [10, 11]. Drug autoinjectors"/>
  <result pre="in several indications, such as rheumatoid arthritis, primary immunodeficiencies, and" exact="multiple sclerosis" post="[10, 11]. Drug autoinjectors have greatly improved the uptake"/>
  <result pre="an Ad vector-encoded antibody followed by an AAV-encoded mAb targeting" exact="anthrax" post="and demonstrated successful rapid and long-lasting expression [20]. Around"/>
  <result pre="useful. Gene therapy studies with viral vectors have previously considered" exact="herpes simplex" post="virus thymidine kinase (HSV-tk) as a potential &quot;suicide�? gene"/>
  <result pre="successful mAb therapy approved for the treatment of hematological B-cell" exact="lymphoma" post="[113]. Nivolumab (anti-PD1) and ipilimumab (anti-CTLA4) are two of"/>
  <result pre="an anti-prostate-specific membrane antigen (anti-PSMA) encoded DNA in a mouse" exact="prostate cancer" post="model [116]. In vivo, their study showed expression for"/>
  <result pre="anti-prostate-specific membrane antigen (anti-PSMA) encoded DNA in a mouse prostate" exact="cancer" post="model [116]. In vivo, their study showed expression for"/>
  <result pre="only target and shrink specific tumors and those in hematological" exact="cancer" post="models in vivo, but they can have a survival"/>
  <result pre="blood mononuclear cells (PBMCs) co-incubated with two different luciferase-expressing lymphoblast" exact="cancer" post="models and showed a dose-dependent blockage of CTLA4, leading"/>
  <result pre="early mouse studies are supportive for continued development of high" exact="cancer" post="value targets. Such developments provide opportunities to broaden the"/>
  <result pre="that receive such high-cost therapies. Cancer: Outlook As the pDNA-mAb" exact="cancer" post="approach continues through preclinical studies, new complementary applications are"/>
  <result pre="first BiTE antibody approved by the FDA. It targets hematological" exact="acute lymphoblastic leukemia" post="by binding to both CD3 T-cell coreceptor and the"/>
  <result pre="BiTE antibody approved by the FDA. It targets hematological acute" exact="lymphoblastic leukemia" post="by binding to both CD3 T-cell coreceptor and the"/>
  <result pre="antibody approved by the FDA. It targets hematological acute lymphoblastic" exact="leukemia" post="by binding to both CD3 T-cell coreceptor and the"/>
  <result pre="These are interesting and promising and likely complementary strategies for" exact="cancer" post="immunotherapy that deserve significant attention. Infectious Disease Control There"/>
  <result pre="successful mAb approved as a standalone intervention to prevent an" exact="infectious disease." post="Synagis costs can be &amp;gt; US$12,000 for a five-dose (15 mg/kg/dose)"/>
  <result pre="raxibacumab and obiltoxaximab, have been approved for treatment of inhalational" exact="anthrax" post="via the FDA Animal Efficacy Rule. The Animal Rule"/>
  <result pre="limitations impede widespread delivery for seasonal outbreaks and epidemics for" exact="influenza" post="viruses. Repeat doses are required to lower HIV viral"/>
  <result pre="The development and manufacturing timeline for rapid response to emerging" exact="infectious disease" post="outbreaks, for example, Ebolavirus, is long and requires cold-chain"/>
  <result pre="DNA- and mRNA-mAbs represent potential rapid delivery platforms for emerging" exact="infectious disease" post="control. Both platforms start with initial antigen-specific mAb sequence"/>
  <result pre="in mice for pDNA-mAbs and mRNA-mAbs targeting dengue virus [101]," exact="influenza" post="A and B viruses [36, 37, 97], Ebolavirus [36,"/>
  <result pre="37, 97], Ebolavirus [36, 42], Zika virus [38], CHIKV [121]," exact="rabies" post="[15], and HIV [49]. Anti-Dengue Virus pDNA-mAbs Close to"/>
  <result pre="estimated 45 million people in the USA were infected by" exact="influenza" post="viruses during the 2017–2018 influenza season, resulting in 810,000"/>
  <result pre="the USA were infected by influenza viruses during the 2017–2018" exact="influenza" post="season, resulting in 810,000 hospitalizations and 61,100 deaths [123]."/>
  <result pre="mAb delivery could have an important impact on lowering overall" exact="influenza" post="disease burden during seasonal influenza epidemics and against potential"/>
  <result pre="important impact on lowering overall influenza disease burden during seasonal" exact="influenza" post="epidemics and against potential pandemic viruses. Yamazaki et al."/>
  <result pre="mouse model to demonstrate preclinical protection against seasonal and pandemic" exact="influenza" post="A and B viruses. Anti-ebolavirus pDNA-mAbs The 2013–2016 Ebolavirus"/>
  <result pre="first demonstration that a nucleic acid-encoded antibody can control an" exact="infectious disease" post="challenge in a larger animal model, further supporting translation"/>
  <result pre="To date, mRNA-mAbs, formulated in LNP, have been evaluated targeting" exact="rabies" post="[15], HIV [49], and CHIKV [127]. Human anti-rabies immunoglobulin"/>
  <result pre="HIV [49], and CHIKV [127]. Human anti-rabies immunoglobulin and the" exact="rabies" post="vaccine must be delivered immediately following potential rabies exposure."/>
  <result pre="and the rabies vaccine must be delivered immediately following potential" exact="rabies" post="exposure. Thran et al. evaluated an mRNA-mAb platform for"/>
  <result pre="pre-exposure (day − 1) and post-exposure (2 h post-infection) protection against lethal" exact="rabies" post="virus challenge in mice. In this study, an anti-influenza"/>
  <result pre="against the virus, with no viral load and protection against" exact="arthritis" post="and muscoskeletal disease in competent C57BL6 mice [127]. They"/>
  <result pre="type III secretion system and Psl exopolysaccharide), protecting against lethal" exact="pneumonia" post="in a mouse challenge model. Lower levels of pro-inflammatory"/>
  <result pre="airway expression of antibody protects old and immunodeficient mice against" exact="influenza" post="virusClin Vaccine Immunol201421111528153310.1128/CVI.00572-1425209558 26.LimberisMPAdamVSWongGGrenJKobasaDRossTMet al.Intranasal antibody gene transfer in"/>
  <result pre="FI6 in mouse airway provides partial protection against a new" exact="avian influenza" post="A virus, H7N9Clin Vaccine Immunol201320121836183710.1128/CVI.00545-1324132603 28.LaursenNSFriesenRHEZhuXJongeneelenMBloklandSVermondJet al.Universal protection against"/>
  <result pre="in mouse airway provides partial protection against a new avian" exact="influenza" post="A virus, H7N9Clin Vaccine Immunol201320121836183710.1128/CVI.00545-1324132603 28.LaursenNSFriesenRHEZhuXJongeneelenMBloklandSVermondJet al.Universal protection against"/>
  <result pre="influenza A virus, H7N9Clin Vaccine Immunol201320121836183710.1128/CVI.00545-1324132603 28.LaursenNSFriesenRHEZhuXJongeneelenMBloklandSVermondJet al.Universal protection against" exact="influenza" post="infection by a multidomain antibody to influenza hemagglutininScience2018362641459860210.1126/science.aaq062030385580 29.LimberisMPTretiakovaANambiarKWongGRacineTCrosariolMet"/>
  <result pre="al.Universal protection against influenza infection by a multidomain antibody to" exact="influenza" post="hemagglutininScience2018362641459860210.1126/science.aaq062030385580 29.LimberisMPTretiakovaANambiarKWongGRacineTCrosariolMet al.Adeno-associated virus serotype 9-expressed ZMapp in mice"/>
  <result pre="following four different methods of administrationBMC Biotechnol20171714310.1186/s12896-017-0365-228506256 32.McNamaraMANairSKHollEKRNA-based vaccines in" exact="cancer" post="immunotherapyJ Immunol Res2015201579452810.1155/2015/79452826665011 33.JulianoRAlamMRDixitVKangHMechanisms and strategies for effective delivery"/>
  <result pre="monoclonal antibodies by gene transfer via electroporation protects against lethal" exact="influenza" post="and Ebola infectionsMol Ther Methods Clin Dev20177748210.1016/j.omtm.2017.09.00329034261 37.ElliottSTCKallewaardNLBenjaminEWachter-RosatiLMcAuliffeJMPatelAet al.DMAb"/>
  <result pre="al.DMAb inoculation of synthetic cross reactive antibodies protects against lethal" exact="influenza" post="A and B infectionsNPJ Vaccines201721810.1038/s41541-017-0020-x29263874 38.EsquivelRNPatelAKudchodkarSBParkDHStettlerKBeltramelloMet al.In vivo delivery"/>
  <result pre="bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a" exact="pneumonia" post="challenge modelNat Commun20178163710.1038/s41467-017-00576-728935938 40.HollevoetKDe VleeschauwerSDe SmidtEVermeireGGeukensNDeclerckPBridging the clinical gap"/>
  <result pre="demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9" exact="influenza" post="virusesMol Ther20172561316132710.1016/j.ymthe.2017.03.03528457665 55.AlbererMGnad-VogtUHongHSMehrKTBackertLFinakGet al.Safety and immunogenicity of a mRNA"/>
  <result pre="influenza virusesMol Ther20172561316132710.1016/j.ymthe.2017.03.03528457665 55.AlbererMGnad-VogtUHongHSMehrKTBackertLFinakGet al.Safety and immunogenicity of a mRNA" exact="rabies" post="vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human"/>
  <result pre="but functions in TLR9-deficient miceJ Immunol2003171115908591210.4049/jimmunol.171.11.590814634101 60.ReidTWarrenRKirnDIntravascular adenoviral agents in" exact="cancer" post="patients: lessons from clinical trialsCancer Gene Ther200291297998610.1038/sj.cgt.770053912522437 61.ZhongLMalaniNLiMBradyTXieJBellPet al.Recombinant"/>
  <result pre="eyePharm Res20183622910.1007/s11095-018-2554-730591984 71.FeldmanRAFuhrRSmolenovIMick RibeiroAPantherLWatsonMet al.mRNA vaccines against H10N8 and H7N9" exact="influenza" post="viruses of pandemic potential are immunogenic and well tolerated"/>
  <result pre="kinase/ganciclovir-mediated apoptotic death of bystander cellsCancer Res19965612269727028665496 83.MesnilMPiccoliCTirabyGWilleckeKYamasakiHBystander killing of" exact="cancer" post="cells by herpes simplex virus thymidine kinase gene is"/>
  <result pre="of bystander cellsCancer Res19965612269727028665496 83.MesnilMPiccoliCTirabyGWilleckeKYamasakiHBystander killing of cancer cells by" exact="herpes simplex" post="virus thymidine kinase gene is mediated by connexinsProc Natl"/>
  <result pre="expression with reduced muscle damageGene Ther20018161264127010.1038/sj.gt.330152211509960 97.YamazakiTNagashimaMNinomiyaDAraiYTeshimaYFujimotoAet al.Passive immune-prophylaxis against" exact="influenza" post="virus infection by the expression of neutralizing anti-hemagglutinin monoclonal"/>
  <result pre="OKT3 (muromonab-CD3): a reviewJ Transpl Coord.19966310911910.7182/prtr.1.6.3.8145l3u1854931829188368 113.BoyiadzisMFoonKAApproved monoclonal antibodies for" exact="cancer" post="therapyExpert Opin Biol Ther2008881151115810.1517/14712598.8.8.115118613766 114.Services CgCfMM. 2019 ASP drug"/>
  <result pre="Accessed 23 Nov 2019. 115.SaltzLBPerspectives on cost and value in" exact="cancer" post="careJAMA Oncol201621192110.1001/jamaoncol.2015.419126501848 116.MuthumaniKMarninLKudchodkarSBPerales-PuchaltAChoiHAgarwalSet al.Novel prostate cancer immunotherapy with a"/>
  <result pre="on cost and value in cancer careJAMA Oncol201621192110.1001/jamaoncol.2015.419126501848 116.MuthumaniKMarninLKudchodkarSBPerales-PuchaltAChoiHAgarwalSet al.Novel" exact="prostate cancer" post="immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibodyCancer"/>
  <result pre="cost and value in cancer careJAMA Oncol201621192110.1001/jamaoncol.2015.419126501848 116.MuthumaniKMarninLKudchodkarSBPerales-PuchaltAChoiHAgarwalSet al.Novel prostate" exact="cancer" post="immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibodyCancer"/>
  <result pre="immunity elicited by DNA-encoded antibody prophylaxis and DNA vaccination against" exact="chikungunya" post="virusJ Infect Dis2016214336937810.1093/infdis/jiw11127001960 122.BradyJMBaltimoreDBalazsABAntibody gene transfer with adeno-associated viral"/>
  <result pre="as a method for HIV preventionImmunol Rev2017275132433310.1111/imr.1247828133808 123.Prevention CfDCa. Estimated" exact="influenza" post="illnesses, medical visits, hospitalizations, and deaths in the United"/>
  <result pre="illnesses, medical visits, hospitalizations, and deaths in the United States—2017–2018" exact="influenza" post="season. In: Influenza (Flu). Centers for Disease Control and"/>
  <result pre="mRNA encoding a potently neutralizing human monoclonal antibody protects against" exact="chikungunya" post="infectionSci Immunol.201910.1126/sciimmunol.aaw66476629435 128.WuXHIV broadly neutralizing antibodies: VRC01 and beyondAdv"/>
 </snippets>
</snippetsTree>
